Proton Cooperative Group Registry of Patients Treated for Pancreatic Cancer – Enrollment and Preliminary Outcomes

Purpose:
Review outcomes for pancreatic cancer patients enrolled on the Proton Cooperative Group (PCG) registry.

Methods:
Data submitted by 5 PCG participating institutions was reviewed for pretreatment characteristics, dose delivered, toxicity recorded and survival.

Results:
From 7/2012 through 2/2015, 26 patients were enrolled on the registry. Excluding 4 patients (1 screen failure; 1 enrolled but not treated; 2 treated for distant metastases), a total of 22 were evaluable. Median age of treated patients was 67 years (range 43 to 93). 8 received postoperative proton therapy to a median dose of 50.40Gy(RBE) (range 45.38 to 59.53). 14 received definitive proton therapy to a median dose of 50.40Gy(RBE) (range 27.88 to 60.70). One patient experienced grade 4 thrombocytopenia and grade 3 fatigue. No other grade 3 or higher toxicities were recorded. Grade 2 gastrointestinal toxicity potentially attributable to proton therapy (nausea, diarrhea, vomiting) was recorded in 8 patients. Median follow up for surviving patients is 5 months. 9 have died. 13 are currently alive.

Conclusions:
Patients treated for non-metastatic pancreatic cancer on the PCG registry appeared to experience limited toxicity attributable to proton therapy.